[go: up one dir, main page]

WO2025181825A3 - Solid state forms of Elacestrant dihydrochloride and their processes for the preparation - Google Patents

Solid state forms of Elacestrant dihydrochloride and their processes for the preparation

Info

Publication number
WO2025181825A3
WO2025181825A3 PCT/IN2025/050280 IN2025050280W WO2025181825A3 WO 2025181825 A3 WO2025181825 A3 WO 2025181825A3 IN 2025050280 W IN2025050280 W IN 2025050280W WO 2025181825 A3 WO2025181825 A3 WO 2025181825A3
Authority
WO
WIPO (PCT)
Prior art keywords
dihydrochloride
elacestrant
preparation
processes
solid state
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IN2025/050280
Other languages
French (fr)
Other versions
WO2025181825A2 (en
Inventor
Thirumalai Rajan Srinivasan
Rajeshwar Reddy Sagyam
Balraju KAMMARI
Sathish KAMUTAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSN Laboratories Pvt Ltd
Original Assignee
MSN Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSN Laboratories Pvt Ltd filed Critical MSN Laboratories Pvt Ltd
Publication of WO2025181825A2 publication Critical patent/WO2025181825A2/en
Publication of WO2025181825A3 publication Critical patent/WO2025181825A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to amorphous solid dispersions comprising Elacestrant dihydrochloride which is chemically known as (6R) -6- (2- (N- (4- (2- (ethyl amino) ethyl) benzyl) -N- ethyl amino) - 4- methoxy phenyl) - 5, 6, 7, 8- tetrahydrona phthalen-2-ol dihydrochloride of formula-1a and one or more pharmaceutically acceptable excipients; their process of preparation. Formula-1a.
PCT/IN2025/050280 2024-02-26 2025-02-25 Solid state forms of Elacestrant dihydrochloride and their processes for the preparation Pending WO2025181825A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202441013791 2024-02-26
IN202441013791 2024-02-26

Publications (2)

Publication Number Publication Date
WO2025181825A2 WO2025181825A2 (en) 2025-09-04
WO2025181825A3 true WO2025181825A3 (en) 2025-10-30

Family

ID=96922037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2025/050280 Pending WO2025181825A2 (en) 2024-02-26 2025-02-25 Solid state forms of Elacestrant dihydrochloride and their processes for the preparation

Country Status (1)

Country Link
WO (1) WO2025181825A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129419A1 (en) * 2017-01-05 2018-07-12 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
WO2023064519A1 (en) * 2021-10-14 2023-04-20 Teva Pharmaceuticals International Gmbh Solid state forms of elacestrant and processes for preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129419A1 (en) * 2017-01-05 2018-07-12 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
WO2023064519A1 (en) * 2021-10-14 2023-04-20 Teva Pharmaceuticals International Gmbh Solid state forms of elacestrant and processes for preparation thereof

Also Published As

Publication number Publication date
WO2025181825A2 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
WO2020140005A8 (en) 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
WO2022115381A8 (en) Compositions and methods for treating cns disorders
NO20062136L (en) Imidazopyrazintyrosin kinase inhibitors
NZ336379A (en) Nitric oxide synthase inhibitor, use and process of preparation
CA2463976A1 (en) N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
DK0559743T3 (en) New hydroxamic acid and N-hydroxyurea derivatives and their use
MY133572A (en) Gyrase inhibitors and uses thereof
MX2022004878A (en) N-(heteroaryl) quinazolin-2-amine derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof.
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
MX2021004457A (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt.
NO963706L (en) Benzene-condensed heterocyclic derivatives and their use
WO2024075070A3 (en) Novel bicyclic heterocyclyl compounds and use thereof
WO2025014877A3 (en) Triazolo wrn inhibitors
KR20010053437A (en) Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators
WO2002094796A3 (en) Benzo[g]quinoxaline derivatives as effective compounds against infectious diseases
SA523441175B1 (en) N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
WO2025181825A3 (en) Solid state forms of Elacestrant dihydrochloride and their processes for the preparation
WO2023244996A3 (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
MX2025010952A (en) Amide derivatives for inhibiting nlrp3 and uses thereof
TW429146B (en) Pharmaceutical composition for prophylaxis and treatment of type I allergic diseases
ES8604167A1 (en) 2-Anilino-1,6-dihydro-6-oxo-5-pyrimidinecarboxylic acid derivatives, processes for the preparation thereof, and antiallergic agent containing the same.
EP0666855A1 (en) 4-CHINOLINYL DERIVATIVES WITH ANTI-HELICOBACTER EFFECT.
MY138996A (en) 4-amino-5-cyanopyrimidine derivatives
WO2024173207A8 (en) Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2- dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-5-yl)-4-chloro-6- cyclopropoxy-3-fluorobenzonitrile
WO2023049369A3 (en) Pyridinyl derivatives as sodium channel activators